Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported … Continua a leggere

First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401

To address the paucity of data in patients with historically poor outcomes, we conducted the single-arm phase IIIb CheckMate 401 study to evaluate the safety and efficacy of nivolumab plus ipilimumab followed by nivolumab monotherapy in clinically diverse patient populations with advanced melanoma. Treatment-naive patients with unresectable stage III-IV melanoma received nivolumab 1 mg/kg plus ipilimumab 3 mg/kg once every 3 weeks (four doses) … Continua a leggere

Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG

Melanomas frequently harbour somatic mutations in BRAF (40%) or NRAS (20%). Impact of NRAS mutations on the therapeutic outcome of immune checkpoint inhibitors (ICI) remains controversial. Potential correlation of the NRAS mutational status and programmed cell death ligand-1 (PD-L1) expression in melanoma is unknown. Advanced, non-resectable melanoma patients with known NRAS mutation status treated with first-line ICI …  Continua a leggere

XXXI IACRLRD SYMPOSIUM 2023
Bologna, 31 agosto – 2 settembre 2023

REAL WORLD EVIDENCE vs RANDOMIZED CLINICAL TRIALS: TWO SIDES OF THE SAME COIN
Napoli, 11 settembre 2023

Fertilità e carcinoma mammario
Udine, 13 settembre 2023

International Summer School on Immuno-Oncology
Verbania, 13 – 16 settembre 2023

Etica in Oncologia
Loreto (AN), 15 – 16 settembre 2023

TRANSLATING SCIENCE INTO SURVIVAL
Milano, 20 – 23 settembre 2023

Corso teorico-pratico sulla metodologia della ricerca clinica
Napoli, 21 settembre 2023

Advanced International Breast Cancer Course (AIBCC)
Padova, 21 – 22 settembre 2023

REAL WORLD EVIDENCE vs RANDOMIZED CLINICAL TRIALS: TWO SIDES OF THE SAME COIN
Bologna, 22 settembre 2023

Lung Cancer
FAD / Milano, 25 settembre 2023

HOT TOPICS IN URO-ONCOLOGIA: PROSTATA, VESCICA E RENE
Palermo, 29 settembre 

Breast Cancer in Autumn
Milano, 29 settembre 2023

XXIX Congresso Nazionale IMI 
Napoli, 29 – 30 settembre – 1 ottobre 2023

Oncologia centrata sulla persona: dalla prevenzione alla “precision-medicine”
Brugnera (PN), 29 – 30 settembre 2023

XXV Congresso Nazionale AIOM
Roma, 10 – 12 novembre 2023